Here are the DEF 14A proxy statements from Pfizer Inc. (PFE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PFE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PFE filings page.
Pfizer Inc. is asking shareholders at its virtual April 23, 2026 annual meeting to elect 12 directors, ratify KPMG as auditor, approve the amended 2019 Stock Plan, hold an advisory vote on executive pay and consider a shareholder proposal for an independent chair.
The proxy highlights 2025 results: total revenue of $62.6 billion versus $63.6 billion with a 2% operational decline, but 6% operational growth excluding COVID-19 products. Pfizer advanced a 102-project R&D pipeline and completed strategic deals including the Metsera acquisition and licensing agreements with 3SBio and YaoPharma.
Cost realignment is expected to deliver about $5.7 billion in net savings by 2026, plus roughly $1.5 billion from manufacturing optimization by 2027. In 2025 the company returned $9.8 billion in cash dividends, invested $10.4 billion in internal R&D and about $8.8 billion in business development, while maintaining a long dividend record and emphasizing board independence and risk oversight.